Evaluation of Target Organs Damage in Hypertensive Patients

Completed

• Conditions: Target Organs Damage; Hypertensive; no Known Cardiovascular; no Known Renal Disease

• Registration Number: NCT01055353
• Lead Sponsor: AstraZeneca

Brief Summary

Evaluation of target organs damage in hypertensive patients with no known cardiovascular (CV) or renal disease, stratified according to level of blood pressure control

Detailed Description

Not available

Study Timeline

• Study Start: 2010-01
• Study First Submitted: 2010-01-21
• Study First Submitted QC: 2010-01-22
• Study First Posted: 2010-01-25
• Primary Completion: 2010-06
• Study Completion: 2010-06
• Status Verified: 2011-05
• Last Update Submitted: 2011-05-11
• Last Update Posted: 2011-05-12

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 1857

Inclusion Criteria

• diagnosis of essential hypertension (treated or untreated); HT not discovered on the day of the consultation; no documented clinical cardiovascular or renal disease.

Exclusion Criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To evaluate the frequency of evaluation of preclinical target organs damage in hypertensive patients with no known cardiovascular or renal disease, by taking blood pressure (controlled or uncontrolled HT*) into account	once / 1 Year

Secondary Outcome Measures

Name	Time	Method
To describe the patient profile (socio-demographic, risk factors, comorbidities, global CV risk level estimated by the doctor and calculated retrospectively [according to ESH 2007]) associated with screening for target organs damage
To describe the modalities of patient follow-up and management
To compare the frequency of evaluation of target organs damage as a function of the modalities of management of CV risk factors at the time of the consultation.

Trial Locations

Locations (1)

Research Site; 🇫🇷 Yvre L Eveque, France